Pharma News

DF-003 by Drug Farm for Chronic Kidney Disease (Chronic Renal Failure): Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

DF-003 overview

DF-003 is under development for the treatment of rare blindness (ROSAH syndrome) and cardio-renal disease, chronic kidney disease (chronic renal failure). It is administered through oral route in the form of capsules. It acts by targeting alpha-protein kinase 1 (ALPK1) and is being developed based on IDInVivo technology.

Drug Farm overview

Drug Farm developing innovative treatments targeting the innate immunity for hepatitis B, cancer, and autoimmune diseases. It is headquartered in Shanghai, China.

For a complete picture of DF-003’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 9 October 2023


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.

Source link
#DF003 #Drug #Farm #Chronic #Kidney #Disease #Chronic #Renal #Failure #Likelihood #Approval

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *